Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is one of the best affordable biotech stocks to invest in now. On September 4, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced positive new data supporting the foundational role of MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM).

The new data from pre-specified analysis showed that “patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression”.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a commercial-stage company that develops therapies for rare diseases with limited or no treatment options. Its product portfolio focuses on rare neurological and sleep conditions, including Idiopathic Hypersomnia, Urea Cycle Disorders, and Niemann-Pick disease type C.

While we acknowledge the potential of ZVRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZVRA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.